ROBERT C. BATTERMAN, M.D.; DELAVAN V. HOLMAN, M.D.; ARTHUR C. DEGRAFF, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Over a period of years, evidence has been accumulating attesting to limitations of the bio-assay for digitalis bodies. Preparations of the same potency with regard to their ability to produce death in a cat or frog will vary markedly in their therapeutic potency as applied to man. Outstanding examples of this discrepancy are the purified digitalis glycosides, digitoxin, (Merck1 or "digitaline nativelle"2) and Verodigen (Gitalin)3, 4 and other members of the digitalis group such as g-strophanthin (Ouabain)5 and Urginin.6 This marked difference among various digitalis bodies has resulted in confusion. To substitute one preparation for another and still maintain the
BATTERMAN RC, HOLMAN DV, DEGRAFF AC. THE THERAPEUTIC EFFECTIVENESS AND POTENCY OF DIGILANID IN THE TREATMENT OF CONGESTIVE HEART FAILURE*. Ann Intern Med. 1941;14:2058–2072. doi: https://doi.org/10.7326/0003-4819-14-11-2058
Download citation file:
Published: Ann Intern Med. 1941;14(11):2058-2072.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use